[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/main/docs/Risk/index.md) >> Individual ID:PBN__Risk_1146 

# __Lack of drug therapy options__

## Category to which it belongs

* [The challenges include reduced surgical education, loss of control, limited diagnostics, slow drug development, inadequate patient monitoring, and lack of drug therapy options.](https://github.com/mm80843/T3.5/blob/main/docs/PBNCategory/PBN__PBNCategory_100.md)

## Closest similar item

* [Lack of novel treatment options](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2189.md)
* [Lack of effective drugs](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2724.md)
* [Lack of Effective Treatment](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1868.md)
* [Insufficient non-pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1603.md)
* [Lack of access to pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1158.md)
* [Ineffective non-pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1490.md)
* [Lack of effective pharmaceutical response](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1602.md)
* [Lack of treatment and resources](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2070.md)
* [Lack of drug therapies for COVID-19](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_935.md)
* [Lack of accessibility of pharmaceutical interventions in developing countries](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_727.md)

## Description of the risk

Limited evidence of the efficacy of drug therapies for treating COVID-19

## Is the risk affecting GBN scales

* [No](https://github.com/mm80843/T3.5/blob/main/docs/RiskGBN/PBN__RiskGBN_0.md)

## Type of the risk

* [physical](https://github.com/mm80843/T3.5/blob/main/docs/RiskHealth/PBN__RiskHealth_0.md)

## Type of impact of the risk (according to ISO37100)

* [Health and care](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Purpose_0.md)

## Type of purpose of the risk (according to ISO37100)

* [Safety and security](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Impact_0.md)

## Mitigations of this risk

* [Conduct clinical trials to determine the efficacy of drug therapies, develop new therapeutics](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1597.md)

## Name of the risk

Delay in effective treatment and management of COVID-19 cases

## Stakeholders who can mitigate this risk

* [medical researchers](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_687.md)
* [pharmaceutical companies](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_124.md)

## Articles mentionning the risk

* [An environmental and health perspective for COVID-19 outbreak: Meteorology and air quality influence, sewage epidemiology indicator, hospitals disinfection, drug therapies and recommendations](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_270.md)

## People affected by this risk

* [individuals infected with covid-19](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_686.md)

## Technologies linked to the risk

* [antiviral drugs](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_236.md)
* [anti-malaria drugs](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_237.md)
* [anti-inflammatory drugs](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_238.md)

## Property: has_RiskType

* [technological](https://github.com/mm80843/T3.5/blob/main/docs/RiskType/PBN__RiskType_5.md)

